Recombinant Mouse Integral membrane protein 2A (Itm2a)

What is ITM2A and what are its basic structural features?

ITM2A (Integral Membrane Protein 2A) is a full-length protein consisting of 263 amino acids. It belongs to the ITM2 family of proteins and is also known by alternative names including E25, Itm2, and Protein E25 . The protein contains transmembrane domains that facilitate its integration into cellular membranes, with specific structural motifs that contribute to its biological functions. The full amino acid sequence begins with M-V-K-I-A-F-N-T-P-T-A-V-Q-K-E-E and continues through a series of hydrophobic and hydrophilic regions that determine its membrane topology .

What methodologies are recommended for detecting endogenous ITM2A?

For reliable detection of endogenous ITM2A in research specimens, quantitative reverse transcription PCR (qRT-PCR) has been effectively utilized. Recommended primer sequences for mouse ITM2A detection by qRT-PCR are as follows:

• Forward: 5′-ATCCTGCAAATTCCCTTCGTG-3′

• Reverse: 5′-CAGGTAAGCAGTCATTCCCTTT-3′

Expression levels can be normalized using appropriate housekeeping genes such as GAPDH. Immunoblotting represents another validated method for protein-level detection, though antibody selection must be carefully considered to ensure specificity for the mouse protein variant .

How can recombinant mouse ITM2A be effectively overexpressed in experimental systems?

Successful overexpression of ITM2A in breast cancer cell lines has been achieved using plasmid transfection techniques. For optimal results in breast cancer cell lines like MCF-7 and MDA-MB-231, transfection with 2.0 μg of ITM2A-encoding plasmid using X-tremeGENE HP DNA Transfection Reagent has been demonstrated to be effective . Transfection efficiency should be validated via qRT-PCR and immunoblotting approximately 48 hours post-transfection before proceeding with functional assays .

What cellular assays are most informative for studying ITM2A function?

Several validated assays provide valuable insights into ITM2A function:

• Migration and invasion assays: Transwell assays have effectively demonstrated that ITM2A overexpression significantly reduces the migration and invasion capacity of breast cancer cells .

• Apoptosis assessment: Flow cytometry analysis has revealed higher apoptosis rates in ITM2A-overexpressing breast cancer cells compared to controls .

• Proliferation and clonogenic assays: Cell viability assays (CCK-8) and colony formation assays conducted over 14 days have demonstrated that ITM2A overexpression attenuates proliferation and reduces clone formation in breast cancer cell lines .

• In vivo tumor growth models: Xenograft models using athymic nude mice have confirmed the tumor-suppressive effects of ITM2A observed in vitro .

What are the quality control considerations for recombinant mouse ITM2A protein?

Commercial recombinant mouse ITM2A protein preparations typically specify ≥85% purity, suitable for analytical techniques such as SDS-PAGE . When working with recombinant protein, researchers should verify protein integrity via SDS-PAGE analysis before experimental application. Additionally, for cell-free expression systems used to produce recombinant ITM2A, validation of proper folding and post-translational modifications may be necessary depending on the intended experimental applications .

What evidence supports ITM2A's role as a tumor suppressor?

Multiple lines of evidence establish ITM2A as a tumor suppressor, particularly in breast cancer:

• Clinical correlation: High ITM2A expression correlates with favorable prognosis in breast cancer patients, as demonstrated through survival analysis using tools like Kaplan-Meier Plotter and PrognoScan .

• In vitro functional data: Overexpression of ITM2A in breast cancer cell lines results in:

  • Reduced migration and invasion capacity

  • Increased apoptosis rates

  • Decreased proliferation and clone formation ability

• In vivo confirmation: Xenograft models have demonstrated that ITM2A overexpression inhibits tumor growth, providing critical validation of in vitro findings .

How does ITM2A influence the tumor microenvironment?

ITM2A appears to influence the tumor microenvironment through its interaction with immune checkpoint molecules. Research has identified a correlation between ITM2A and programmed death ligand 1 (PD-L1) expression in breast cancer tissues . This relationship suggests ITM2A may modulate anti-tumor immune responses, potentially through mechanisms involving tumor-infiltrating lymphocytes (TILs). Gene Set Enrichment Analysis (GSEA) performed on RNA-Seq profiles from breast cancer patients stratified by ITM2A expression levels has further elucidated pathways through which ITM2A influences the tumor microenvironment .

What molecular mechanisms underlie ITM2A's tumor suppressive effects?

The molecular mechanisms through which ITM2A exerts its tumor suppressive effects have been partially elucidated through RNA sequencing studies of ITM2A-overexpressing cells. Differentially expressed genes (DEGs) were identified using the DEGseq R package with criteria of adjusted p<0.05 and |log2-fold-change|>2 . Functional annotation and enrichment analysis performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) have mapped ITM2A's influence on critical cellular pathways involved in proliferation, migration, and apoptosis .

How can researchers leverage RNA-sequencing to investigate ITM2A-mediated effects?

RNA-sequencing provides powerful insights into the transcriptional changes induced by ITM2A. A validated protocol involves:

• Transfecting cells with ITM2A-encoding plasmid (2.0 μg) for 72 hours

• Extracting total RNA using Trizol reagent

• Preparing libraries from 2 μg of purified RNA

• Sequencing on an Illumina NovaSeq platform (150 bp paired-end reads)

• Analyzing differentially expressed genes using the DEGseq R package

• Performing pathway analysis using "clusterProfiler" and "enrichplot" R packages

This approach has successfully identified key molecular pathways regulated by ITM2A in breast cancer models.

What are the considerations for studying ITM2A in relation to immune checkpoint molecules?

When investigating ITM2A's relationship with immune checkpoint molecules like PD-L1, researchers should:

• Verify expression correlation through multiple methods:

  • qRT-PCR on patient-derived samples

  • Flow cytometry for protein-level correlation

  • Analysis of public databases (TCGA, GEO)

• Consider the influence of tumor-infiltrating lymphocytes (TILs) using tools like Tumor Immune Estimation Resource (TIMER)

• Validate findings across different molecular subtypes of breast cancer, as immune checkpoint dynamics may vary significantly between subtypes

How can xenograft models be optimized for studying ITM2A function?

Effective xenograft models for studying ITM2A function have been established using the following approach:

• Transfect breast cancer cell lines (e.g., MCF-7) with ITM2A-encoding plasmid

• Inject 5 × 10^6 cells per mouse subcutaneously into athymic nude mice

• Monitor tumor volume using the formula: 0.5 × (minor tumor axis)^2 × (major tumor axis)

• Perform magnetic resonance imaging (plain scan and enhanced) for comprehensive assessment of tumor growth

• Conduct tissue analysis post-sacrifice to evaluate ITM2A expression maintenance and histological characteristics

This approach provides a robust in vivo system for validating ITM2A's tumor-suppressive properties.

What are common challenges in maintaining ITM2A expression stability?

Researchers frequently encounter challenges with stability of ITM2A expression in experimental systems. To address these:

• Validate expression levels regularly throughout long-term experiments using qRT-PCR and immunoblotting

• For cell line work, maintain cells at low passage numbers (less than 30 passages) to prevent drift in expression profiles

• Consider creating stable cell lines using selection markers if transient transfection yields inconsistent results

• Store recombinant protein according to manufacturer recommendations to maintain integrity

How should researchers interpret conflicting data regarding ITM2A function?

When encountering conflicting results regarding ITM2A function:

• Consider cell type-specific effects – ITM2A may function differently across various cancer cell lines

• Evaluate expression levels critically – both overexpression and knockdown approaches can yield valuable but potentially different insights

• Validate key findings using multiple methodological approaches

• Account for potential differences between mouse and human ITM2A when translating findings across species

What future research directions will advance understanding of ITM2A biology?

Several promising research directions could significantly advance understanding of ITM2A biology:

• Investigate post-translational modifications of ITM2A and their functional significance

• Explore ITM2A's role across diverse cancer types beyond breast cancer

• Develop conditional knockout mouse models to evaluate tissue-specific functions

• Investigate potential therapeutic approaches targeting the ITM2A pathway

• Further characterize the mechanistic relationship between ITM2A and immune checkpoint molecules